Mucosolvan 1mal Täglich (Ambroxol Hydrochloride)

Ambroxol Hydrochloride, the active ingredient in Mucosolvan 1mal Täglich, is a mucolytic presented as an oral dosage form for oral use. It helps to reduce mucus viscosity and is employed in the management of acute and chronic bronchitis, COPD and other respiratory tract infections characterized by thick secretions.

GNH USA supplies Mucosolvan 1mal Täglich as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies, clinics and research institutions worldwide, with a focus on quality assurance and regulatory compliance across multiple continents.

Ambroxol Hydrochloride is used as a mucolytic agent to improve clearance of thick respiratory secretions in several pulmonary conditions.

Acute bronchitis: facilitates removal of viscous mucus, easing cough and improving breathing. Chronic bronchitis: reduces mucus thickness, supporting airway patency and symptom relief. COPD: aids in thinning sputum, helping patients clear secretions during exacerbations. Respiratory tract infections with thick mucus: enhances mucociliary transport, assisting recovery.

Ambroxol Hydrochloride is generally well tolerated, but several adverse reactions have been reported.

Common Side Effects: - Nausea - Taste disturbance (bitter or metallic) - Diarrhea - Abdominal discomfort - Headache - Skin rash

Serious or Rare Side Effects: - Anaphylactic reactions - Stevens‑Johnson syndrome or severe skin eruptions - Eosinophilic pneumonia - Hepatic enzyme elevation - Neutropenia - Acute hypersensitivity with angioedema

When prescribing Ambroxol Hydrochloride, consider the following precautions to ensure safe use. - Pediatric use: follow prescriber guidance, especially for children under six years. - Renal impairment: dose may need adjustment in severe renal dysfunction. - Hepatic impairment: use with caution in patients with liver disease. - Concomitant antitussives: may diminish the mucolytic benefit. - Known hypersensitivity: avoid in individuals with documented allergy to ambroxol or related compounds. - Store at ambient temperature: keep below 25 °C, retain in original packaging and protect from moisture.

Ambroxol Hydrochloride has a low potential for drug‑drug interactions, but certain combinations require attention.

Major Interactions (Avoid): - Concurrent use of other mucolytics: may increase risk of gastrointestinal irritation. - Strong CYP3A4 inhibitors (e.g., ketoconazole): could raise ambroxol plasma levels. - Anticholinergic agents: may counteract the secretory stimulation effect.

Moderate Interactions (Monitor Closely): - Antitussive preparations containing codeine: may reduce mucolytic efficacy. - Bronchodilators (β2‑agonists): monitor for additive cough suppression. - Antibiotics for respiratory infections: observe for any change in tolerability.